These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10499606)

  • 1. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
    Bergan RC; Reed E; Myers CE; Headlee D; Brawley O; Cho HK; Figg WD; Tompkins A; Linehan WM; Kohler D; Steinberg SM; Blagosklonny MV
    Clin Cancer Res; 1999 Sep; 5(9):2366-73. PubMed ID: 10499606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
    Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G
    Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
    Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ; Redman BG; Esper PS; Flaherty LE
    Am J Clin Oncol; 1996 Oct; 19(5):500-3. PubMed ID: 8823479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.
    Johnston SR; Gumbrell LA; Evans TR; Coleman RE; Smith IE; Twelves CJ; Soukop M; Rea DW; Earl HM; Howell A; Jones A; Canney P; Powles TJ; Haynes BP; Nutley B; Grimshaw R; Jarman M; Halbert GW; Brampton M; Haviland J; Dowsett M; Coombes RC;
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):341-8. PubMed ID: 14722733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
    Senzer N; Arsenau J; Richards D; Berman B; MacDonald JR; Smith S
    Am J Clin Oncol; 2005 Feb; 28(1):36-42. PubMed ID: 15685033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megestrol acetate in the treatment of hormone refractory prostate cancer.
    Osborn JL; Smith DC; Trump DL
    Am J Clin Oncol; 1997 Jun; 20(3):308-10. PubMed ID: 9167760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen in refractory metastatic carcinoma of the prostate.
    Glick JH; Wein A; Padavic K; Negendank W; Harris D; Brodovsky H
    Cancer Treat Rep; 1980; 64(6-7):813-8. PubMed ID: 7427966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
    Berry WR; Hathorn JW; Dakhil SR; Loesch DM; Jackson DV; Gregurich MA; Newcomb-Fernandez JK; Asmar L
    Clin Prostate Cancer; 2004 Sep; 3(2):104-11. PubMed ID: 15479494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
    Hamilton M; Dahut W; Brawley O; Davis P; Wells-Jones T; Kohler D; Duray P; Liewehr DJ; Lakhani N; Steinberg SM; Figg WD; Reed E
    Acta Oncol; 2003; 42(3):195-201. PubMed ID: 12852695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF; Skarlos D; Bafaloukos D; Kosmidis P; Anagnostopoulos A; Aravantinos G; Dimopoulos MA;
    Urology; 2003 Jun; 61(6):1211-5. PubMed ID: 12809899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.